{"id":46478,"date":"2026-01-01T11:35:24","date_gmt":"2026-01-01T11:35:24","guid":{"rendered":"https:\/\/quickassetsmarket.com\/index.php\/2026\/01\/01\/why-corcept-therapeutics-stock-crashed-today-and-what-comes-next\/"},"modified":"2026-01-01T11:35:24","modified_gmt":"2026-01-01T11:35:24","slug":"why-corcept-therapeutics-stock-crashed-today-and-what-comes-next","status":"publish","type":"post","link":"https:\/\/quickassetsmarket.com\/index.php\/2026\/01\/01\/why-corcept-therapeutics-stock-crashed-today-and-what-comes-next\/","title":{"rendered":"Why Corcept Therapeutics stock crashed today and what comes next?"},"content":{"rendered":"
<\/div>\n

Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data<\/a> to support the efficacy of relacorilant, its candidate treatment for Cushing\u2019s syndrome.<\/p>\n

The setback cast doubt on CORT\u2019s pipeline strength and triggered a sharp re-evaluation by analysts. It underscores the market\u2019s sensitivity to regulatory developments in small-cap drug makers.<\/p>\n

Following today\u2019s plunge, Corcept stock is down 70% versus its year-to-date high in late March.<\/p>\n

What FDA setback means for Corcept stock<\/h2>\n

FDA\u2019s request for more evidence on relacorilant\u2019s effectiveness has materially weakened investor confidence in Corcept\u2019s near-term growth.<\/p>\n

The drug was expected to be a key revenue driver in the Cushing\u2019s syndrome market, where CORT already sells Korlym.<\/p>\n

With relacorilant now facing delays or potential rejection, analysts have removed it from their financial models for this indication.<\/p>\n

Korlym itself is under pressure from generic competition, particularly from Teva Pharmaceuticals. This leaves CORT stock with limited upside in its core therapeutic area.<\/p>\n

The regulatory hurdle not only impacts future sales but also raises questions about the robustness of Corcept Therapeutics\u2019 clinical data and trial strategy.<\/p>\n

CORT shares\u2019 price action may still be overdone<\/h2>\n

Despite the major FDA setback, some analysts believe the market reaction may have overshot the fundamentals.<\/p>\n

Truist Securities, for example, slashed its price objective on Corcept shares to $50, acknowledging the recent news is significantly bearish for the biotech firm.<\/p>\n

However, the investment firm maintained a \u201cbuy\u201d rating, with the downwardly revised price target still indicating potential upside of more than 40% from here.<\/p>\n

\u201cWe see value in Korlym in Cushing\u2019s with upside from relacorilant in PROC,\u201d its analysts noted, referring to platinum-resistant ovarian cancer.<\/p>\n

After today\u2019s crash, Corcept Therapeutics is going for a price-to-sales (P\/S) ratio of about 10 only, which isn\u2019t particularly expensive for a fast-growing biotech company.<\/p>\n

In short, while the FDA news is undeniably negative, the removal of relacorilant for Cushing\u2019s  altogether from valuation models may be premature, especially if the management can address the agency\u2019s concerns.<\/p>\n

Should you buy Corcept on the pullback?<\/h2>\n

CORT shares may be worth owning heading into 2026, as it isn\u2019t one of those unprofitable biotech names<\/a>.<\/p>\n

In the latest reported quarter, the company had nearly $20 million in net income and $208 million in revenue \u2013 up some 14% on a year-over-year basis.<\/p>\n

Moreover, Corcept\u2019s balance sheet remains strong, and its ongoing research in ovarian cancer could unlock new revenue streams.<\/p>\n

Korlym, despite generic headwinds, continues to generate cash flow, and relacorilant\u2019s potential in oncology remains intact.<\/p>\n

For long-term investors, the current valuation may offer an attractive entry point, especially if management can navigate regulatory challenges and diversify its pipeline.<\/p>\n

The selloff has reset expectations, but the fundamentals suggest Corcept is far from broken. With execution and clarity, the stock could rebound meaningfully in the months ahead.<\/p>\n

The post Why Corcept Therapeutics stock crashed today and what comes next?<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing\u2019s syndrome. The setback cast doubt on CORT\u2019s pipeline strength and triggered a sharp re-evaluation by analysts. It underscores the market\u2019s sensitivity to regulatory developments in small-cap drug makers. <\/p>\n","protected":false},"author":1,"featured_media":46479,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-46478","post","type-post","status-publish","format-standard","has-post-thumbnail","category-investing"],"_links":{"self":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/46478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/comments?post=46478"}],"version-history":[{"count":0,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/posts\/46478\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media\/46479"}],"wp:attachment":[{"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/media?parent=46478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/categories?post=46478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quickassetsmarket.com\/index.php\/wp-json\/wp\/v2\/tags?post=46478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}